Provexis PLC - Half-year Report
Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the
Provexis plc
UNAUDITED INTERIM RESULTS FOR SIX MONTHS TO
Provexis plc ("Provexis" or the "Company"), the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces its unaudited interim results for the six months ended
Highlights
· Total revenue for the period
· Provexis Ireland Limited, the Group's new Irish subsidiary company, started trading in
· The new long term commercial partnership with dsm-firmenich ('DSM') has progressed well during the period, with continuing interest from some significant global customers. The commercial partnership is based on: (i) a Premix and Market-Ready Solutions supply agreement for Fruitflow II SD; and (ii) the use of Fruitflow to confer health benefits in modulating the gut microbiome of humans.
· In
· In
· The share issues to DSM Venturing BV are of direct benefit to the Company's cash resources and net assets, and they will help the Company to fund a wholly new production run of Fruitflow II SD which will be required in the early months of 2025.
· Planned launch by BYHEALTH, a circa
· BYHEALTH has been working since 2015 on an extensive regulatory submission to the Chinese State Administration for Market Regulation ('SAMR') for Fruitflow, seeking to establish a new permitted health function claim for foods such as Fruitflow that can demonstrate an anti-platelet effect.
· In
· Underlying operating loss* for the period of
· Total cash inflow from operating activities for the period of
· Cash of
*Loss from operations, adjusted for (i) share-based payments of
Provexis Chairman
'The Company is pleased to report on another strong period of progress, to include
Total revenue increased by 103% (relative to the prior 6 months ended
Sales of Fruitflow II SD in the half year from
The Company is dealing with numerous sales enquiries from existing and new customers for further direct sales of Fruitflow in 2025 and beyond.
The new long term commercial partnership with dsm-firmenich ('DSM') has progressed well, with continuing interest from some significant global customers. The commercial partnership is based on: (i) a Premix and Market-Ready Solutions supply agreement for Fruitflow II SD; and (ii) the use of Fruitflow to confer health benefits in modulating the gut microbiome of humans.
Provexis has been working with BYHEALTH for more than eight years to support the planned launch of a number of Fruitflow based products in the Chinese market. Clinical studies conducted in
In
Fruitflow is well placed to play an important role in the Chinese cardiovascular health market under the permitted health function claim legislation, and we look forward to working closely with BYHEALTH seeking to maximise the commercial success of this agreement for the benefit of both companies.
The Company has developed a strong, long lasting and wide-ranging patent portfolio for Fruitflow, and it owns outright four existing patent families for Fruitflow. The new microbiome patent application takes this to a potential total of five patent families, with potential patent protection now running out to 2042. The four existing patent families have a truly global footprint, and the Company also holds other valuable intellectual property and trade secrets for Fruitflow. The intellectual property for Fruitflow is of fundamental importance to the Company and its current and future commercial partners, to include DSM and BYHEALTH, and it underpins the numerous commercial opportunities which the Company and its partners are pursuing for Fruitflow.
The Company expects that: (i) the significant changes to the sales and supply chain structure for Fruitflow from
The Company would like to thank its customers and shareholders for their continued support, and the Board remains strongly positive about the outlook for Fruitflow and the Provexis business for the coming year and beyond.'
For further information please contact:
|
Provexis plc
|
Tel: 07490 391888 |
|
Allenby Capital Limited (Nominated Adviser and Broker)
|
Tel: 020 3328 5656
|
Chairman and CEO's statement
The Company has had an active and successful first six months of the year, and it has made further progress with the commercial prospects of its innovative, patented Fruitflow® heart-health ingredient.
DSM Nutritional Products - new agreements for Fruitflow®
Provexis entered into a long-term Alliance Agreement with DSM in 2010 to commercialise Fruitflow through sales as an ingredient to brand owners in the food, beverage and dietary supplement categories, with a contractual term for the Agreement which ran to
More than 100 regional consumer healthcare brands have now been launched by direct customers of DSM, and a number of further regional brands have been launched through DSM's distributor channels. An increasing number of commercial projects have been initiated by DSM with prospective customers in recent years, including some prospective customers which are part of global businesses, and the total projected annual sales value of the prospective sales pipeline for Fruitflow, which is now shared across Provexis and DSM, continues to stand at a substantial multiple of existing annual sales.
In
The Company also announced the filing of a new patent application in
Under the terms of the two new agreements with DSM, and the
· DSM's existing and prospective customers for Fruitflow as a straight ingredient (not a Premix or Market-Ready solution) transferred to become direct customers of Provexis from
· A royalty is payable to DSM on the gross profits generated from Fruitflow sales to customers transferred from DSM over the first four years of the Transfer of Business agreement.
· From
· A new partnership was agreed with DSM in 2022 relating to the gut microbiome patent, giving DSM preferential access to the use, marketing, and sale of Fruitflow based products which are based on the patent, subject to certain milestones which have been agreed between the parties. In addition to the patent's core claim for Fruitflow, for modulating gut microbiota to confer a number of health benefits, the patent also sets out some potential new uses for Fruitflow in treating a wide variety of human health conditions, beyond Fruitflow's existing established use in heart-health. The global digestive health market size was
· The results of the successful gut microbiome human study have been submitted for publication in a peer reviewed scientific journal www.sciencedirect.com/science/article/pii/S0022316622131275.
· DSM conducted a strong launch of the new microbiome technology in
· Provexis will sell Fruitflow as a straight ingredient to DSM exclusively for use in DSM's Premix Solutions and Market-Ready Solutions businesses, with DSM then looking to sell the resulting Premix and Market-Ready Solutions products on to its customers. DSM's Premix and Market-Ready Solutions businesses are part of DSM's Customized Solutions business which also offers personalised nutrition solutions to customers, a rapidly developing growth area. The Company looks forward to supporting DSM and its Premix and Market-Ready Solutions customers for many years to come.
· A number of DSM's customers for Fruitflow which have been transferred to Provexis have been Fruitflow customers for several years, including some distributor customers which sell Fruitflow on to third parties. The Company has been progressing these sales relationships since the Transfer of Business agreement was announced in
From
1. Former DSM customers for Fruitflow;
2. DSM and its Premix and Market-Ready Solutions businesses, which will leverage the resources and relationships of DSM in some of the major global markets, and seek to commercialise the gut microbiome patent;
3. New customers for Fruitflow as a straight ingredient;
4. BYHEALTH and its customers, through the Company's long-term supply and distribution agreement for Fruitflow with BYHEALTH; and
5. The Group's Fruitflow+ Omega-3 dietary supplement product which is sold direct to consumers, the Group will also look to serve its Chinese Cross-Border e-commerce distributor for this product in
The Company is in discussions with a number of third parties seeking to progress new sales and distribution opportunities for Fruitflow, and it can be contacted for all Fruitflow sales enquiries by email at fruitflow@provexis.com.
Fruitflow® transfer arrangements from
The customer transfer process from DSM to Provexis has progressed well, with sales commencing to customers for Fruitflow II SD (Fruitflow II SD is Fruitflow as an ingredient, in Spray Dried powder form) in
|
Revenue |
Unaudited |
Unaudited |
Audited |
|
|
six months |
six months |
year |
|
|
ended |
ended |
ended |
|
|
30 September |
30 September |
31 March |
|
|
2024 |
2023 |
2024 |
|
|
£ |
£ |
£ |
|
|
|
|
|
|
|
|
|
|
|
Fruitflow II SD ingredient |
724,817 |
298,879 |
651,845 |
|
Fruitflow+ Omega-3 |
60,531 |
88,655 |
150,119 |
|
|
785,348 |
387,534 |
801,964 |
Total revenue during the six months ended
Sales of Fruitflow II SD in the half year from
Loss from operations for the period was
Underlying operating loss for the period (being the loss from operations, adjusted for (i) share-based payments of
In
In
The share issues to DSM Venturing BV are of direct benefit to the Company's cash resources and net assets, and they will help the Company to fund a wholly new production run of Fruitflow II SD which will be required in the early months of 2025.
A royalty is payable to DSM on the gross profits generated from Fruitflow sales to customers transferred from DSM over the first four years of the Transfer of Business agreement, entered into by the Company in
Fruitflow II SD is currently manufactured in the EU. Rules of origin under the post BREXIT trade deal announced in
BYHEALTH Co., Ltd.
In
The BYHEALTH Agreement, which followed the Company's extensive work with BYHEALTH over the last eight years, took full effect from
Under the BYHEALTH Agreement Provexis is responsible for the manufacture, supply and sale of Fruitflow to BYHEALTH, and BYHEALTH is responsible for the manufacture, marketing, and sale of Fruitflow based functional food and dietary supplement finished products in the Territories, through BYHEALTH's extensive sales network. BYHEALTH also has exclusive rights to act as the distributor of Fruitflow as an ingredient in the Territories.
Provexis and BYHEALTH will seek to collaborate on research and development projects which may result in the development and approval of Fruitflow as a drug, for potential sale and distribution in the Territories.
Regulatory progress in
Provexis has been working with BYHEALTH for more than eight years to support the planned launch of a number of Fruitflow based products in the Chinese market. Clinical studies conducted in
The Chinese regulatory system for functional health food ingredients, such as Fruitflow, is governed by the State Administration for Market Regulation (the 'SAMR') and it is based on a defined list of permitted health function claims which brand owners are permitted to use on product labels.
The SAMR provides the possibility of adding new health function claims to the list, with claims needing to demonstrate a relationship between a food or nutrient and a consequent health improvement, subject to evaluation and verification by the SAMR.
SAMR certified functional health foods are required to use a blue cap / blue hat logo on their product packaging, which identifies products as approved functional health foods in
BYHEALTH has been working on an extensive regulatory submission to the SAMR seeking to establish a new permitted health function claim for foods such as Fruitflow that can demonstrate an anti-platelet effect, inhibiting platelet function and conferring beneficial health effects.
On
On
The significance of these major developments for Fruitflow in
The Company has previously stated that if BYHEALTH is successful in obtaining a new permitted health function claim in
Fruitflow+ dietary supplement products
Fruitflow+ Omega-3 is available to purchase from the Company's subscription focussed e-commerce website www.fruitflowplus.com, and from Amazon
The Fruitflow+ Omega-3 business reported sales in the period of
Fruitflow+ Omega-3 has a social media presence on Facebook www.facebook.com/FruitflowPlus, Instagram www.instagram.com/fruitflowplus and Twitter / X https://twitter.com/FruitflowPlus.
The Company is seeking to expand further its commercial activities with Fruitflow+ Omega-3 and other Fruitflow+ combination products, and it is currently in dialogue with some other potential international direct selling customers.
Intellectual property
The Company is responsible for filing and maintaining patents and trade marks for Fruitflow, and patent coverage for Fruitflow now includes the following patent families which are all owned outright by Provexis:
|
Patent family
|
Developments in the period from Sep-24 to Dec-24 |
|
Improved Fruitflow / Fruit Extracts Improved Fruitflow / Fruit Extracts, with patents granted by the European Patent Office in
Patents have been granted in thirteen other major territories to include
|
Patent applications (seeking additional patent protection) are pending in
|
|
Antihypertensive (blood pressure lowering) effects This patent was originally developed in collaboration with the University of Oslo, and it has now been granted for Fruitflow in
In
|
Patent applications are pending in
|
|
Fruitflow with nitrates in mitigating exercise-induced inflammation and for promoting recovery from intense exercise Patents have been granted around
Further patent protection is being sought in three territories, with potential patent protection out to
|
Patent applications are pending in
|
|
Fruitflow for air pollution The use of Fruitflow in protecting against the adverse effects of air pollution on the body's cardiovascular system.
Laboratory work has shown that Fruitflow can reduce the platelet activation caused by airborne particulate matter, such as that from diesel emissions, by approximately one third.
US, Australian, Brazilian, Indonesian, Israeli, Japanese Malaysian and Taiwanese patents have been secured and there are pending applications in nine jurisdictions (including the US where a further application has been filed) which extends potential patent protection for Fruitflow out to
|
Patent applications are pending in nine global territories.
|
|
Fruitflow to confer health benefits in modulating the gut microbiome of humans The Company filed a patent application in
The international procedure concluded in
|
Patent applications have been filed in 15 global territories. |
Capital structure and funding
The Company is seeking to maximise the commercial returns that can be achieved from its Fruitflow technology, and the Company's cost base and its resources continue to be very tightly managed. The Company remains keen to minimise dilution to shareholders and it is focussed on moving into profitability as Fruitflow revenues increase, but while the Company remains in a loss-making position and / or significant growth phase, it may need to raise funds in the future to meets its working capital requirements.
The Company has needed to hold Fruitflow II SD in stock from
In
In
The share issues to DSM Venturing BV are of direct benefit to the Company's cash resources and net assets, and they will help the Company to fund a wholly new production run of Fruitflow II SD which will be required in the early months of 2025.
The size / volume and therefore cost of a wholly new production run of Fruitflow II SD will be determined with reference to the Company's best estimate of demand for Fruitflow over the next 24 months, and the Company is currently in dialogue with its existing and prospective customers for Fruitflow II SD, seeking their assistance as best possible with this volume estimate. The forecasting process involves a considerable degree of uncertainty, subject to existing and new customers' changing plans, requirements and regulatory progress, and inevitably there is a wide range of possible outcomes in terms of overall forecast demand.
The production process for Fruitflow II SD takes place in two stages, which need to be booked with its outsourced supply chain partners in advance of production taking place. The Company is in close dialogue with all key parties in its supply chain for Fruitflow, to include: (i) maximum capacity planning; (ii) production cost and other efficiencies; and (iii) the potential requirement for much larger batches of Fruitflow II SD to be made at relatively short notice.
In the coming months, based on its current level of cash, the Group may need to raise further equity finance or potentially new loan finance, subject in large part to the size / volume of new production runs of Fruitflow II SD which the Company may need to commission, with larger production runs inevitably requiring more cash at the outset.
Considering the success of previous fundraisings and the current performance of the business, the Directors have a reasonable expectation of raising sufficient additional equity capital or new loan finance to continue in operational existence for the foreseeable future. Subject to the outcome of ongoing negotiations with a third party, the Company might also be able to hold some of its future stock requirements on a consignment basis, only paying for the stock when it was required for sale.
For these reasons the Directors are of the opinion that at
Outlook
The Company is pleased to report on another strong period of progress, to include
Total revenue increased by 103% (relative to the prior 6 months ended
Sales of Fruitflow II SD in the half year from
The Company is dealing with numerous sales enquiries from existing and new customers for further direct sales of Fruitflow in 2025 and beyond.
The new long term commercial partnership with dsm-firmenich ('DSM') has progressed well, with continuing interest from some significant global customers. The commercial partnership is based on: (i) a Premix and Market-Ready Solutions supply agreement for Fruitflow II SD; and (ii) the use of Fruitflow to confer health benefits in modulating the gut microbiome of humans.
Provexis has been working with BYHEALTH for more than eight years to support the planned launch of a number of Fruitflow based products in the Chinese market. Clinical studies conducted in
In
Fruitflow is well placed to play an important role in the Chinese cardiovascular health market under the permitted health function claim legislation, and we look forward to working closely with BYHEALTH seeking to maximise the commercial success of this agreement for the benefit of both companies.
The Company has developed a strong, long lasting and wide-ranging patent portfolio for Fruitflow, and it owns outright four existing patent families for Fruitflow. The new microbiome patent application takes this to a potential total of five patent families, with potential patent protection now running out to 2042. The four existing patent families have a truly global footprint, and the Company also holds other valuable intellectual property and trade secrets for Fruitflow. The intellectual property for Fruitflow is of fundamental importance to the Company and its current and future commercial partners, to include DSM and BYHEALTH, and it underpins the numerous commercial opportunities which the Company and its partners are pursuing for Fruitflow.
The Company expects that: (i) the significant changes to the sales and supply chain structure for Fruitflow from
The Company would like to thank its customers and shareholders for their continued support, and the Board remains strongly positive about the outlook for Fruitflow and the Provexis business for the coming year and beyond.
Chairman CEO
|
Consolidated statement of comprehensive income |
|
Unaudited |
Unaudited |
Audited |
|
Six months ended |
|
six months |
six months |
year |
|
|
|
ended |
ended |
ended |
|
|
|
30 September |
30 September |
31 March |
|
|
|
2024 |
2023 |
2024 |
|
|
|
£ |
£ |
£ |
|
|
Notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue |
|
785,348 |
387,534 |
801,964 |
|
Cost of goods |
|
(512,000) |
(249,870) |
(518,169) |
|
Gross profit |
|
273,348 |
137,664 |
283,795 |
|
|
|
|
|
|
|
Selling and distribution costs |
|
(32,811) |
(32,744) |
(65,706) |
|
Research and development costs |
|
(123,716) |
(140,225) |
(301,722) |
|
Administrative costs - share based payment charges |
|
(49,207) |
(60,526) |
(121,051) |
|
Administrative costs - other |
|
(215,153) |
(180,504) |
(398,908) |
|
Loss from operations |
|
(147,539) |
(276,335) |
(603,592) |
|
|
|
|
|
|
|
Finance income |
|
890 |
1,029 |
1,594 |
|
Loss before taxation |
|
(146,649) |
(275,306) |
(601,998) |
|
|
|
|
|
|
|
Taxation |
|
(12,500) |
8,200 |
13,880 |
|
|
|
|
|
|
|
Loss and total comprehensive loss for the period |
(159,149) |
(267,106) |
(588,118) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Attributable to: |
|
|
|
|
|
Owners of the parent |
|
(159,149) |
(267,106) |
(586,243) |
|
Non-controlling interest |
|
- |
- |
(1,875) |
|
Loss and total comprehensive loss for the period |
(159,149) |
(267,106) |
(588,118) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per share to owners of the parent |
|
|
|
|
|
Basic and diluted - pence |
3 |
(0.01) |
(0.01) |
(0.03) |
|
|
|
|
|
|
|
Consolidated statement of financial position |
|
Unaudited |
Unaudited |
Audited |
|
|
|
30 September |
30 September |
31 March |
|
|
|
2024 |
2023 |
2024 |
|
|
Notes |
£ |
£ |
£ |
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
Current assets |
|
|
|
|
|
Inventories |
|
152,755 |
145,863 |
136,520 |
|
Trade and other receivables |
|
144,760 |
264,410 |
125,479 |
|
Corporation tax asset |
|
46,680 |
41,000 |
46,680 |
|
Cash and cash equivalents |
|
478,199 |
318,819 |
189,357 |
|
Total current assets |
|
822,394 |
770,092 |
498,036 |
|
|
|
|
|
|
|
Total assets |
|
822,394 |
770,092 |
498,036 |
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
Current liabilities |
|
|
|
|
|
Trade and other payables |
|
(471,006) |
(319,017) |
(307,448) |
|
Total current liabilities |
|
(471,006) |
(319,017) |
(307,448) |
|
|
|
|
|
|
|
Total liabilities |
|
(471,006) |
(319,017) |
(307,448) |
|
|
|
|
|
|
|
Total net assets |
|
351,388 |
451,075 |
190,588 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital and reserves attributable to |
|
|
|
|
|
owners of the parent company |
|
|
|
|
|
Share capital |
|
2,262,945 |
2,217,822 |
2,217,822 |
|
Share premium reserve |
|
18,928,940 |
18,703,321 |
18,703,321 |
|
Merger reserve |
|
6,599,174 |
6,599,174 |
6,599,174 |
|
Retained earnings |
|
(26,905,922) |
(26,537,368) |
(26,795,980) |
|
|
|
885,137 |
982,949 |
724,337 |
|
Non-controlling interest |
|
(533,749) |
(531,874) |
(533,749) |
|
Total equity |
|
351,388 |
451,075 |
190,588 |
|
Consolidated statement of cash flows |
Unaudited |
Unaudited |
Audited |
|
|
six months |
six months |
year |
|
|
ended |
ended |
ended |
|
|
30 September |
30 September |
31 March |
|
|
2024 |
2023 |
2024 |
|
|
£ |
£ |
£ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from operating activities |
|
|
|
|
Loss after tax |
(159,149) |
(267,106) |
(588,118) |
|
Adjustments for: |
|
|
|
|
Finance income |
(890) |
(1,029) |
(1,594) |
|
Taxation charge / (Tax credit receivable) |
12,500 |
(8,200) |
(13,880) |
|
Share-based payment charge - share options |
49,207 |
60,526 |
121,051 |
|
Changes in inventories |
(16,235) |
181,934 |
191,277 |
|
Changes in trade and other receivables |
(19,281) |
(203,436) |
(64,505) |
|
Changes in trade and other payables |
163,558 |
130,680 |
119,111 |
|
Net cash flow from operations |
29,710 |
(106,631) |
(236,658) |
|
|
|
|
|
|
Taxation |
(12,500) |
45,160 |
45,160 |
|
Total cash flow from operating activities |
17,210 |
(61,471) |
(191,498) |
|
|
|
|
|
|
Cash flow from investing activities |
|
|
|
|
Interest received |
890 |
1,169 |
1,734 |
|
Total cash flow from investing activities |
890 |
1,169 |
1,734 |
|
|
|
|
|
|
Cash flow from financing activities |
|
|
|
|
Proceeds from issue of share capital - purchase of inventory |
270,742 |
- |
- |
|
Total cash flow from financing activities |
270,742 |
- |
- |
|
|
|
|
|
|
Net change in cash and cash equivalents |
288,842 |
(60,302) |
(189,764) |
|
Opening cash and cash equivalents |
189,357 |
379,121 |
379,121 |
|
Closing cash and cash equivalents |
478,199 |
318,819 |
189,357 |
|
Consolidated statement of changes in equity |
Share |
Share |
Merger |
Retained |
Total equity |
Non- |
Total |
|
|
capital |
premium |
reserve |
earnings |
attributable to owners of |
controlling interests |
equity |
|
|
|
|
|
|
the parent |
|
|
|
|
|
|
|
|
|
|
|
|
|
£ |
£ |
£ |
£ |
£ |
£ |
£ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At |
2,217,822 |
18,703,321 |
6,599,174 |
(26,330,788) |
1,189,529 |
(531,874) |
657,655 |
|
|
|
|
|
|
|
|
|
|
Share-based charges - share options |
- |
- |
- |
60,526 |
60,526 |
- |
60,526 |
|
|
|
|
|
|
|
|
|
|
Total comprehensive expense for the period |
- |
- |
- |
(267,106) |
(267,106) |
- |
(267,106) |
|
|
|
|
|
|
|
|
|
|
At |
2,217,822 |
18,703,321 |
6,599,174 |
(26,537,368) |
982,949 |
(531,874) |
451,075 |
|
|
|
|
|
|
|
|
|
|
Share-based charges - share options |
- |
- |
- |
60,525 |
60,525 |
- |
60,525 |
|
|
|
|
|
|
|
|
|
|
Total comprehensive expense for the period |
- |
- |
- |
(319,137) |
(319,137) |
(1,875) |
(321,012) |
|
|
|
|
|
|
|
|
|
|
At |
2,217,822 |
18,703,321 |
6,599,174 |
(26,795,980) |
724,337 |
(533,749) |
190,588 |
|
|
|
|
|
|
|
|
|
|
Share-based charges - share options |
- |
- |
- |
49,207 |
49,207 |
- |
49,207 |
|
|
|
|
|
|
|
|
|
|
Issue of shares - inventory purchased |
45,123 |
225,619 |
- |
- |
270,742 |
- |
270,742 |
|
|
|
|
|
|
|
|
|
|
Total comprehensive expense for the period |
- |
- |
- |
(159,149) |
(159,149) |
- |
(159,149) |
|
|
|
|
|
|
|
|
|
|
At |
2,262,945 |
18,928,940 |
6,599,174 |
(26,905,922) |
885,137 |
(533,749) |
351,388 |
|
|
|
|
|
|
|
|
|
1. General information, basis of preparation and accounting policies
General information
Provexis plc is a public limited company incorporated and domiciled in the
The main activities of the Group are those of developing, licensing and selling the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.
Basis of preparation
This condensed financial information has been prepared using accounting policies consistent with International Financial Reporting Standards in the European Union (IFRS).
The same accounting policies, presentation and methods of computation are followed in this condensed financial information as are applied in the Group's latest annual audited financial statements, except as set out below. While the financial figures included in this half-yearly report have been computed in accordance with IFRS applicable to interim periods, this half-yearly report does not contain sufficient information to constitute an interim financial report as that term is defined in IAS 34.
Use of non-GAAP profit measure - underlying operating profit
The directors believe that the operating loss before share based payments measure provides additional useful information for shareholders on underlying trends and performance. This measure is used for internal performance analysis. Underlying operating loss is not defined by IFRS and therefore may not be directly comparable with other companies' adjusted profit measures. It is not intended to be a substitute for, or superior to IFRS measurements of profit.
The interim financial information does not constitute statutory accounts as defined in section 434 of the Companies Act 2006 and has been neither audited nor reviewed by the Company's auditors Shipleys LLP pursuant to guidance issued by the Auditing Practices Board.
The results for the year ended
The interim report for the six months ended
This announcement was approved by the Board of Provexis plc for release on
Going concern
Under the terms of the DSM Transfer of Business agreement which was announced in
The Company has needed to hold Fruitflow II SD in stock from
In
In
The share issues to DSM Venturing BV for (i) the inventory purchases and (ii) the settlement of an estimated royalty liability are of direct benefit to the Company's cash resources and net assets, and they will help the Company to fund a wholly new production run of Fruitflow II SD which will be required in the early months of 2025.
The size / volume and therefore cost of a wholly new production run of Fruitflow II SD will be determined with reference to the Company's best estimate of demand for Fruitflow over the next 24 months, and the Company is currently in dialogue with its existing and prospective customers for Fruitflow II SD, seeking their assistance as best possible with this volume estimate. The forecasting process involves a considerable degree of uncertainty, subject to existing and new customers' changing plans, requirements and regulatory progress, and inevitably there is a wide range of possible outcomes in terms of overall forecast demand.
The production process for Fruitflow II SD takes place in two stages, which need to be booked with its outsourced supply chain partners in advance of production taking place. The Company is in close dialogue with all key parties in its supply chain for Fruitflow, to include (i) maximum capacity planning, (ii) production cost and other efficiencies and (iii) the potential requirement for much larger batches of Fruitflow II SD to be made at relatively short notice.
In the coming months, based on its current level of cash, the Group may need to raise further equity finance or potentially new loan finance, subject in large part to the size / volume of new production runs of Fruitflow II SD which the Company may need to commission, with larger production runs inevitably requiring more cash at the outset.
Considering the success of previous fundraisings and the current performance of the business, the Directors have a reasonable expectation of raising sufficient additional equity capital or new loan finance to continue in operational existence for the foreseeable future. Subject to the outcome of ongoing negotiations with a third party, the Company might also be able to hold some of its future stock requirements on a consignment basis, only paying for the stock when it was required for sale.
For these reasons the Directors are of the opinion that at
Accounting policies
The accounting policies applied are consistent with those of the annual financial statements for the year ended
2. Segmental reporting
The Group's operating segments are determined based on the Group's internal reporting to the Chief Operating Decision Maker (CODM). The CODM has been determined to be the Board of Directors as it is primarily responsible for the allocation of resources to segments and the assessment of performance of the segments. The performance of operating segments is assessed on revenue.
The CODM uses revenue as the key measure of the segments' results as it reflects the segments' underlying trading performance for the financial period under evaluation. Revenue is reported separately to the CODM and all other reports are prepared as a single business unit.
|
Revenue |
Unaudited |
Unaudited |
Audited |
|
|
six months |
six months |
year |
|
|
ended |
ended |
ended |
|
|
30 September |
30 September |
31 March |
|
|
2024 |
2023 |
2024 |
|
|
£ |
£ |
£ |
|
|
|
|
|
|
|
|
|
|
|
Fruitflow II SD ingredient |
724,817 |
298,879 |
651,845 |
|
Fruitflow+ Omega-3 |
60,531 |
88,655 |
150,119 |
|
|
785,348 |
387,534 |
801,964 |
3. Earnings per share
Basic earnings per share amounts are calculated by dividing the profit attributable to owners of the parent by the weighted average number of ordinary shares in issue during the period.
The loss attributable to equity holders of the Company for the purpose of calculating the fully diluted loss per share is identical to that used for calculating the basic loss per share. The exercise of share options would have the effect of reducing the loss per share and is therefore anti-dilutive under the terms of IAS 33 'Earnings per Share'.
Basic and diluted loss per share amounts are in respect of all activities.
There were 178,500,000 share options in issue at
|
|
Unaudited |
Unaudited |
Audited |
|
|
six months |
six months |
year |
|
|
ended |
ended |
ended |
|
|
30 September |
30 September |
31 March |
|
|
2024 |
2023 |
2024 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss for the period attributable to owners of the parent - £ |
159,149 |
267,106 |
586,243 |
|
|
|
|
|
|
Weighted average number of shares |
2,261,712,366 |
2,217,821,523 |
2,217,821,523 |
|
|
|
|
|
|
Basic and diluted loss per share - pence |
0.01 |
0.01 |
0.03 |
4. Share capital and Total Voting Rights
At
The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
5. Cautionary statement
This document contains certain forward-looking statements with respect to the financial condition, results and operations of the business. These statements involve risk and uncertainty as they relate to events and depend on circumstances that will incur in the future. Nothing in this interim report should be construed as a profit forecast.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE